ClinicalTrials.gg
Active, not recruitingNCT06923761EMITT-1Updated Oct 13, 2026

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

A Phase 1/2 interventional study of Module 1 (GRWD5769 on its own as monotherapy) and Module 2 (GRWD5769 in combination with cemiplimab, administered IV) in Advanced Solid Malignancy, sponsored by Grey Wolf Therapeutics. Active, not recruiting at 28 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Grey Wolf Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled May 2023, registered Mar 2025).
Updated Oct 13, 2026Now Active, not recruiting1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.

Read the detailed description

GRWD5769 is as a potential new treatment for advanced or metastatic solid malignancies. GRWD5769 works by stopping an enzyme in the body, called endoplasmic reticulum aminopeptidase 1 (ERAP1), from working. ERAP1 is part of how the body recognizes the presence of a cancer tumour and helps trigger the immune system to fight the cancer. However, in patients with cancer, the immune system cells can become exhausted and no longer work effectively. By blocking ERAP1 it makes the tumour look different to the immune system and so the immune system starts fighting the cancer again. GRWD5769 has the potential of producing clinically meaningful improvements in monotherapy and in combination with therapy like cemiplimab (Libtayo®) by enhancing the antitumour immune response.

Who can participate? Patients with advanced or metastatic solid malignancy aged 18 years or older.

What does the study involve? This study consists of Module 1 (Parts A to D), which will look at the effects of GRWD5769 when given alone and Module 2 (Parts A to D) which will look at the effects of GRWD5769 when given in combination with another anticancer drug called Libtayo® (cemiplimab).

02

Conditions studied

  • Advanced Solid Malignancy

Keywords

  • Oncology
  • ERAP 1
  • Solid tumors
  • TMB-H
  • NSCLC
  • Lung cancer
  • Cervical cancer
  • HCC - Hepatocellular Carcinoma
  • Liver cancer
  • Head and Neck Squamous Cell Carcinoma
  • SCCHN
  • Urothelial cancer
  • immuno oncology
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 300 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Grey Wolf Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written .
  2. Male or female, ≥ 18 years of age.
  3. An performance status of 0 or 1.
  4. Willing to permit access to stored historical tumour tissue and prior tumour radiological assessments and tumour biomarker data (if available).
  5. Able to take oral medications and be willing to record daily adherence to the study drug.
  6. Female participants must be of non-, or, if of childbearing potential must have a negative pregnancy test (as required by protocol), must use a highly effective method of combined with a condom and not donate ova (for the protocol specified period of time).
  7. Male participants must use a condom and their female participant must also use a highly effective method of contraception (for the protocol specified period of time), if engaging in sexual intercourse with a female partner who could become pregnant and not donate sperm.
  8. Estimated of at least 3 months, in the opinion of the PI.
  9. Willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.
  10. Participant has per 1.1/
  11. Participant has or histologically confirmed locally advanced or solid for which no further standard of care (SoC) therapy is available (or no SoC therapy exists), or who have been offered and declined SoC therapy, or are intolerant of SoC therapy.

    Module 1 (Part B) and Module 2 (Part B) Only

  12. Participant has at least one tumour lesion amenable to serial and is willing to provide consent for biopsies and has measurable disease per RECIST 1.1/iRECIST, excluding the lesion(s) identified for biopsy.

    Module 2 (Part C and Part D)

    Cohort 1 (Cervical)

  13. Participants with histologically confirmed persistent, recurrent or metastatic cervical cancer who are not amenable to curative therapy.
  14. Participants should have received at least 3 months anti-PD(L)-1 therapy (± bevacizumab, chemotherapy, ADC or other immunotherapy e.g. ) and this should have included at least a 10-week period without progression.
  15. Participants may enrol in the study immediately following progression on the first line CPI or may have received 1 further line of systemic cancer therapy after progression on CPI.

    Cohort 2 (Hepatocellular Carcinoma)

  16. Participants with histologically confirmed hepatocellular carcinoma who are not amenable to curative therapy and ineligible for loco-regional therapy.
  17. Participants should have received at least 3 months first line anti-PD(L)-1 containing therapy and this should have included at least a 10-week period without progression per Investigator assessment.
  18. Participants may enrol in the study immediately following progression on the first line CPI or may have received 1 further line of systemic cancer therapy after progression on CPI.
  19. Participant has score class A liver function.

    Cohort 3 (Moderate to High TMB)

  20. Participants with cytologically or histologically confirmed advanced, recurrent or metastatic disease, which is not amenable to curative therapy, in up to 5 types of solid tumour with moderate to high median TMB (NSCLC, urothelial, SCCHN, gastric/gastro-oesophageal adenocarcinoma, oesophageal SCC).
  21. Participants should have received at least ≥ 3 months first line anti-PD(L)-1 (± chemotherapy, ADC, pemetrexed or other immunotherapy e.g. anti-CTLA-4) and this should have included at least a 10-week period without progression.
  22. Participants may enrol in the study immediately following progression on the first line CPI or may have received 1 further line of systemic cancer therapy after progression on CPI.

    Module 2 Part D only (pMMR/MSS-CRC)

  23. Participants with histologically confirmed unresectable pMMR/MSS-CRC, without current or prior liver metastases
  24. Participants should have received at least one line of therapy in the advanced/metastatic setting and should have received therapies according to local standard practice, unless ineligible or intolerant to the treatment
  25. Participants may not have received more than 2 lines of cytotoxic chemotherapy

Exclusion criteria

Exclusion Criteria:

  1. Prior therapy with an ERAP1 inhibitor.
  2. Any other within the past 3 years, with the exception of cervical intraepithelial neoplasia and nonmelanoma skin cancer.
  3. Any unresolved toxicity (except alopecia) from prior therapy of ≥ Grade 1. Participants with Grade 2 toxicity that is not (e.g., alopecia, vitiligo), or that is deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled.
  4. Active or documented history of disease (within 2 years) requiring systemic therapy, or participant is immunocompromised for any other reason (as determined by the Investigator).
  5. Spinal cord compression or , unless asymptomatic, stable, and not requiring for at least 4 weeks (if stable and requiring no intervention, the participant can be enrolled in the study).
  6. Uncontrolled seizures.
  7. Active infection requiring therapy within 14 days prior to the day of first dose of IMP.
  8. Severe or uncontrolled medical condition (e.g., severe , severe Parkinson's disease, active inflammatory bowel disease) or psychiatric condition.
  9. Active bleeding diatheses.
  10. Participant has received an organ transplant.
  11. Known active , , or infection (HIV).
  12. Participant is breastfeeding or pregnant.
  13. Receipt of licenced or unlicenced cytotoxic, noncytotoxic or small molecule treatment for the malignancy within 28 days or 5 half-lives, whichever is shorter prior to the day of first dose of IMP.
  14. Receipt of oral corticosteroids (at a dose > 10 mg prednisone/day or equivalent) within 14 days (except for subjects receiving corticosteroids for adrenal insufficiency).
  15. Receipt of St John's Wort or of another concomitant medication, herbal supplement, or food that is a strong inhibitor or inducer of enzymes within 14 days.
  16. Receipt of a blood transfusion (blood or blood products) within 7 days.
  17. Impaired hepatic or renal function.
  18. Liver function deteriorating in a manner that would likely make the participant ineligible per protocol specified requirements.
  19. Other evidence of impaired hepatic synthesis function.
  20. Inadequate bone marrow reserve or organ function.
  21. Any prior history of persistent (> 4 weeks) severe pancytopenia due to previous therapy rather than to disease (ANC \< 0.5 × 10\^9/L or \< 50 x 10\^9/L).
  22. Cardiac dysfunction or other clinically significant cardiac pathology likely to impair the participants ability to participate in the study.
  23. Mean > 450 ms for males or > 470 ms for females.
  24. Any clinically important abnormalities in rhythm, conduction, or morphology on resting . Controlled atrial fibrillation is permitted.
  25. Any factor that in the Investigator's opinion increases the risk of QTc prolongation or arrythmic events.
  26. In the opinion of the Investigator, unlikely to comply with study procedures, restrictions, or requirements.
  27. A history of haemolytic anaemia or marrow aplasia.
  28. Has received a live-virus vaccination within 28 days. Note: seasonal flu or COVID vaccines that do not contain live virus are permitted.
  29. History of Grade 3 or 4 pneumonitis or interstitial lung disease within the last 5 years, or other clinically significant pulmonary pathology likely to impair ability to participate in the study.

    Module 2 all Parts and Module 1A Crossover Participants Only

  30. Has discontinued a prior due to toxicity.
  31. to cemiplimab or any of its , or to cemiplimab per approved local labelling.
  32. Has experienced ≥ Grade 2 immune-mediated AE on this study (applies to crossover participants only).

    Module 2 Part D only - pMMR/MSS CRC dose optimisation cohort

  33. Participants with unresectable pMMR/MSS CRC may not have purely peritoneal disease
  34. Participants with unresectable pMMR/MSS CRC may not have had prior CPI / immunotherapy
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Module 1 (GRWD5769 on its own as monotherapy)

    Drug: Module 1 (GRWD5769 on its own as monotherapy)

  • Experimental
    Module 2 (GRWD5769 in combination with cemiplimab, administered IV)

    Drug: Module 2 (GRWD5769 in combination with cemiplimab, administered IV)

Interventions

  • DrugModule 1 (GRWD5769 on its own as monotherapy)

    Module 1 will initially be conducted in 4 study parts: Part A: Monotherapy dose escalation (where the safety of increasing doses of GRWD5769 will initially be assessed in a small group of patients, overseen by a safety review committee) Part B: (Optional) Monotherapy dose expansion part (to look at the effect of GRWD5769 on the body, and of the body on GRWD5769, at particular dose levels to include evaluation of biopsies of tumour tissue) Part C: (Optional) Intra-patient dose escalation (where a patient may receive three different GRWD5769 doses so that blood levels at each dose can be measured in an individual) Part D: Monotherapy dose expansion group(s) (where a dose of GRWD5769 may be chosen to be evaluated in specific types of cancer)

  • DrugModule 2 (GRWD5769 in combination with cemiplimab, administered IV)

    Module 2 will initially be conducted as 3 study parts, similar to those above, but looking at GRWD5769 when given in combination with cemiplimab: Part A: Combination therapy dose escalation (like Module 1 Part A) Part B: (Optional) Combination therapy dose expansion part (like Module 1 Part B) Part C: Combination therapy dose expansion group(s) (where a dose of GRWD5769 given with cemiplimab will be evaluated in specific types of cancer) Part D: Randomised dose optimisation, combination therapy (where 3 doses of GRWD5769 given with cemiplimab will be evaluated in specific types of cancer)

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent and treatment related AEs

    Incidence of treatment emergent and treatment related AEs assessed from start of study drug to 30 days post last dose of GRWD5769 (Module 1) or to 90 days post last dose of cemiplimab (Module 2 Parts A-C).

    Time frame: From first dose to 30 days after last dose of GRWD5769 for Module 1 and 90 days after last dose of cemiplimab for Module 2 Parts A-C.

  2. Incidence of Dose limiting toxicities (DLT)

    Incidence of Dose limiting toxicities (DLT) during the DLT period which commences Cycle 0 Day 1 and continues to 21 days after Cycle 1 Day 1

    Time frame: End of cycle 1 (each cycle is 21 days)

  3. Comparative efficacy (for Module 2D only)

    Comparative efficacy will be evaluated or assessed using the change in dimension over time of RECIST Target Lesions from baseline and on-study scans recorded at weeks 8 and 16

    Time frame: From baseline to week 16

Secondary outcomes

  1. GRWD5769 Plasma PK Trough concentration

    Time frame: Up to approximately 1 year

  2. Objective response rate (ORR)

    Preliminary efficacy of GRWD5769 will be assessed by: Tumour response (ORR) by RECIST 1.1 or iRECIST as determined by CT/MRI scans performed every 8 weeks until participant disease progression or withdrawal.

    Time frame: Up to approximately 1 year

  3. Disease specific tumour markers

    Changes in any applicable disease-specific tumour markers assessed pre-treatment, Day 1 of each cycle from Cycle 2 onwards, at each 6-weekly safety extension visit, at the end of study visit and at follow up visit 30 days post last dose of GRWD5769.

    Time frame: Up to approximately 1 year

  4. GRWD5769 Plasma PK Cmax

    Cmax = Maximum observed concentration

    Time frame: Up to approximately 1 year

  5. GRWD5769 Plasma PK Tmax

    Tmax = Time to maximum observed concentration

    Time frame: Up to approximately 1 year

  6. GRWD5769 Plasma PK AUC0-t

    AUC0-t = Area under the concentration-time curve

    Time frame: Up to approximately 1 year

  7. GRWD5769 Plasma PK Half-life

    Time frame: Up to approximately 1 year

  8. GRWD5769 Plasma PK Oral Clearance

    Time frame: Up to approximately 1 year

  9. GRWD5769 Plasma PK Vss/F

    Vss/F = Absorption-dependent apparent volume of distribution in steady state

    Time frame: Up to approximately 1 year

  10. Disease Control Rate (DCR)

    Preliminary efficacy of GRWD5769 will be assessed by: Tumour response (DCR) by RECIST 1.1 or iRECIST as determined by CT/MRI scans performed every 8 weeks until participant disease progression or withdrawal.

    Time frame: Up to approximately 1 year

  11. Stable Disease Rate (SDR)

    Preliminary efficacy of GRWD5769 will be assessed by: Tumour response (SDR) by RECIST 1.1 or iRECIST as determined by CT/MRI scans performed every 8 weeks until participant disease progression or withdrawal.

    Time frame: Up to approximately 1 year

  12. Time To Response (TTR)

    Preliminary efficacy of GRWD5769 will be assessed by: Tumour response (TTR) by RECIST 1.1 or iRECIST as determined by CT/MRI scans performed every 8 weeks until participant disease progression or withdrawal.

    Time frame: Up to approximately 1 year

  13. Duration Of Response (DOR)

    Preliminary efficacy of GRWD5769 will be assessed by: Tumour response (DOR) by RECIST 1.1 or iRECIST as determined by CT/MRI scans performed every 8 weeks until participant disease progression or withdrawal.

    Time frame: Up to approximately 1 year

  14. Progression - Free Survival (PFS)

    Preliminary efficacy of GRWD5769 will be assessed by: Tumour response (PFS) by RECIST 1.1 or iRECIST as determined by CT/MRI scans performed every 8 weeks until participant disease progression or withdrawal.

    Time frame: Up to approximately 1 year

  15. Number of treatment emergent and treatment related AEs (for Module 2D only)

    Incidence of treatment emergent and treatment related AEs assessed from start of study drug to 90 days post last dose of cemiplimab (for Module 2D only).

    Time frame: 90 days after last dose of cemiplimab

  16. Incidence of Dose limiting toxicities (DLT) (for Module 2D only)

    Incidence of Dose limiting toxicities (DLT) during the DLT period which commences Cycle 0 Day 1 and continues to 21 days after Cycle 1 Day 1

    Time frame: End of cycle 1 (each cycle is 21 days)

  17. Overall Survival

    Preliminary efficacy of GRWD5769 will be assessed by: Overall survival assessed from start of study drug until participant withdrawal or death (for Module 2C and 2D only).

    Time frame: Up to approximately 1 year

07

Study locations

28 sites
08

References and documents

Individual participant data

Plan to share: No — IPD may not be shared for this Phase 1 study, or the IPD plan may be updated at a later point.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Apr 2027, 47 months after the start.

Of 102 non-industry phase 1/2 interventional studies under Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 111. This study's planned 47 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 11, 2025
StartActual
May 21, 2023
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Sites
1 site removed
Show 1 removed
  • GenesisCare Research · Adelaide, Australia
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • GenesisCare Research · Adelaide, Australia
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06923761
Lead sponsor
Grey Wolf Therapeutics
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
May 21, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion